Key opinion leaders discuss the importance of immunization registries and data surveys for pharmacists and technicians in identifying and reaching target populations.
A discussion on how to effectively train pharmacists and technicians on immunization coverage, administration and follow-up.
Experts in the field of immunization discuss key vaccine capture points to bridge the treatment gap.
A discussion regarding the population gap in vaccine coverage and the patient groups at high-risk if not immunized.
Troy Trygstad, PharmD, MBA, PhD, leads a discussion on the current rates of immunization amongst various age groups and how to effectively administer vaccines to the general population.
Following their discussion of available agents for irritable bowel syndrome with constipation (IBS-C), the panel considers how to optimally stratify patients.
Experts break down the appropriate use of guanylate cyclase-C agonists for irritable bowel syndrome with constipation (IBS-C).
Switching their focus to irritable bowel syndrome with constipation (IBS-C), panelists evaluate the use of laxatives and lubiprostone, respectively.
In the setting of irritable bowel syndrome with diarrhea (IBS-D), key opinion leaders reflect on the role of eluxadoline.
A panel of experts provide their perspective on the use of rifaximin to manage patients with irritable bowel syndrome with diarrhea (IBS-D).
An overview of 5-HT3 directed therapy’s role in treating irritable bowel syndrome with diarrhea (IBS-D).
Experts consider the role of antispasmodics and neuromodulators in managing patients with irritable bowel syndrome (IBS).